{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:09:42Z","timestamp":1791252582485,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":3782,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1994,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Loss of dopaminergic innervation of the striatum results in overactivity of the glutamatergic pathways from the subthalamic nucleus to the internal segment of the globus pallidus and the substantia nigra pars reticulata, the output nuclei of the basal ganglia. Previous work has shown that local blockade of glutamate receptors in the internal segment of the globus pallidus or substantia nigra pars reticulata leads to marked suppression of parkinsonian signs. We have now examined whether systemic administration of a glutamate receptor antagonist has antiparkinsonian effects in rodent and primate models of Parkinson's disease. Remacemide hydrochloride is an anticonvulsant, neuroprotective compound with antagonist activity at the <jats:italic>N<\/jats:italic>\u2010methyl\u2010<jats:sc>D<\/jats:sc>\u2010aspartate receptor ion channel. In normal rats and monoaminedepleted rats, remacemide hydrochloride did not cause locomotor hyperactivity, unlike MK\u2010801. When monoaminedepleted rats were treated with a subthreshold dose of levodopa methylester, remacemide hydrochloride (5\u201340mg\/kg, orally) caused a dose\u2010dependent increase in locomotor activity. Moreover, remacemide hydrochloride (10 mg\/kg, orally) potentiated the effects of each suprathreshold dose of levodopa methylester tested (100\u2013200 mg\/kg, intraperitoneally). Parkinsonian rhesus monkeys were tested with oral doses of vehicle plus vehicle, vehicle plus levodopa\u2010carbidopa, and remacemide hydrochloride (5 mg\/kg) plus levodopa\u2010carbidopa. Blinded clinical scoring of videotapes revealed that treatment with remacemide hydrochloride plus levodopa\u2010carbidopa was substantially better than levodopa\u2010carbidopa plus vehicle or vehicle plus vehicle. The effects of remacemide hydrochloride lasted at least 5 hours. We conclude that certain <jats:italic>N<\/jats:italic>\u2010methyl\u2010<jats:sc>D<\/jats:sc>\u2010aspartate receptor antagonists have antiparkinsonian actions and low potential for side effects. Clinical trials of remacemide hydrochloride in patients with Parkinson's disease may be warranted.<\/jats:p>","DOI":"10.1002\/ana.410350605","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T14:41:23Z","timestamp":1104590483000},"page":"655-661","source":"Crossref","is-referenced-by-count":127,"title":["Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease"],"prefix":"10.1002","volume":"35","author":[{"given":"J. Timothy","family":"Greenamyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Ovadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kurlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don M.","family":"Gash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01485901"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/1801200a0"},{"key":"e_1_2_1_4_2","first-page":"787","article-title":"Der L\u20102,3\u2010dioxyphenylalanin (L\u2010dopa)\u2014Effekt bei der Parkinson\u2010Akinese","volume":"73","author":"Birkmayer W","year":"1961","journal-title":"Wein Klin Wochenschr"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196702162760703"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1041416"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(89)90074-X"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(89)90007-6"},{"key":"e_1_2_1_9_2","first-page":"65","article-title":"Behavioral pharmacology of glutamate in the basal ganglia","volume":"38","author":"Schmidt WJ","year":"1992","journal-title":"J Neural Transm"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2402638"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(89)90120-6"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870060404"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)90103-0"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)90177-1"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90952-8"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870060208"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300513"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(92)90086-9"},{"key":"e_1_2_1_19_2","unstructured":"National Institutes of Health. Guide for the care and use of laboratory animals. NIH Publication No. 86\u201023 1985"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90176-G"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870060205"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280411"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430020204"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(93)90005-5"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90595-7"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00806918"},{"key":"e_1_2_1_27_2","first-page":"809","article-title":"Chronic alterations in jejunal myoelectric activity in rats due to MPTP","volume":"253","author":"Eaker EY","year":"1987","journal-title":"Am J Physiol"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(92)90006-N"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90952-8"},{"key":"e_1_2_1_30_2","unstructured":"PorterRHP GreeneJG GreenamyreJT.Polysynaptic regulation of basal ganglia glutamate receptors induced by unilateral nigrostriatal dopamine depletion. Abstract presented at the Third National Parkinson Foundation International Symposium on Parkinson's disease Washington DC 1993"},{"key":"e_1_2_1_31_2","first-page":"189","volume-title":"Excitatory amino acids","author":"Carlsson M","year":"1992"},{"key":"e_1_2_1_32_2","first-page":"402","article-title":"Opposite effects of NMDA receptor blockade on dopaminergic D1\u2010 and D2\u2010 mediated behavior in the 6\u2010hydroxydopamine model of turning: relationship with c\u2010fos expression","volume":"260","author":"Morelli M","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410340413"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410350605","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410350605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:57:42Z","timestamp":1698195462000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410350605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1994,6]]}},"alternative-id":["10.1002\/ana.410350605"],"URL":"https:\/\/doi.org\/10.1002\/ana.410350605","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,6]]}}}